2017 Press Releases

Keyword Search
 
December 13, 2017
Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017
- Generation 2 Manufacturing Process Selected for All Ongoing and Future TIL Clinical Development - - Company Reports Updated Results for Cohort 2 in Melanoma Study - - Two New Studies in NSCLC Patients in Collaboration with Moffitt Cancer Center and MedImmune - SAN CARLOS, Calif., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, is hosting a... More »
December 13, 2017
Iovance Biotherapeutics Expands Pipeline of TIL Therapies into Lung Cancer
Moffitt Cancer Center Phase 1 Study Combining TIL and Nivolumab Initiated in NSCLC Patients Iovance/MedImmune Clinical Collaboration to Initiate with Start of Phase 2 Study in PD-1/PDL-1 Naïve NSCLC Patients 1H 2018 SAN CARLOS, Calif., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that patient enrollment has begun in a st... More »
December 7, 2017
Iovance Biotherapeutics to Webcast Analyst Day on Wednesday, December 13, 2017
SAN CARLOS, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will webcast its Analyst Day on Wednesday, December 13, 2017 from 9:00 a.m. to 12:00 p.m. ET in New York, NY. The event will highlight Iovance’s lead clinical programs, LN-144 for the treatment of metastatic melanoma, LN-145 for recurrent and/or metas... More »
November 28, 2017
Iovance Biotherapeutics to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
SAN CARLOS, Calif., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Dr. Maria Fardis, PhD, MBA, President and Chief Executive Officer, will participate in a fireside chat at the Evercore ISI Biopharma Catalyst/Deep Dive Conference on Thursday, November 30, 2017 at 11:00 a.m. ET in Boston, MA. A live audio webcast of the ... More »
November 13, 2017
Iovance Biotherapeutics to Present at the Jefferies 2017 London Healthcare Conference
SAN CARLOS, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Chief Financial Officer, Timothy Morris, will present a Company  overview and pipeline update at the Jefferies 2017 London Healthcare Conference on Thursday, November 16, 2017 at 10:00 a.m. GMT in London, United Kingdom. A live audio webcast of the prese... More »
November 9, 2017
Iovance Biotherapeutics Announces New LN-144 Phase 2 Clinical Data from Metastatic Melanoma Trial to be Presented at SITC Meeting
Late-Breaking Poster Shows Early Efficacy Data in Nine Patients Treated with Cryopreserved TIL Product LN-144; Comparable Safety to Non-Cryopreserved LN-144 SAN CARLOS, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced early efficacy and safety data from Cohort 2 of the ongoing Phase 2 LN-144 metastatic melanoma trial (C-... More »
October 31, 2017
Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results
- Company to Host Conference Call at 4:30pm ET Today - SAN CARLOS, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its third quarter 2017 financial results and provided a corporate update. "In the third quarter of 2017 we continued to make significant progress in the clinic as the first patient was dosed with LN-145 in th... More »
October 25, 2017
Iovance Biotherapeutics to Host Conference Call to Discuss Third Quarter 2017 Financial Results and Provide a Corporate Update on Tuesday, October 31, 2017
SAN CARLOS, Calif., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its third quarter 2017 financial and operating results after the close of the U.S. financial markets on Tuesday, October 31, 2017. Management will host a conference call and live audio webcast to discuss these results and provide a corporate ... More »
October 11, 2017
Iovance Biotherapeutics Announces Six Abstracts to be Presented at the Upcoming 2017 SITC Annual Meeting
SAN CARLOS, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that six abstracts, including one late-breaking abstract highlighting its TIL therapy, will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting from November 8-12, 2017 in National Harbor, Maryland.  The late-break... More »
September 25, 2017
Iovance Biotherapeutics, Inc. Announces Closing of $57.5 Million Common Stock Public Offering
SAN CARLOS, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the closing of its public offering of 8,846,154 shares of its common stock at a public offering price of $6.50 per share, before underwriting discounts. The shares of common stock issued and sold in the offering at the closing include 1,153,846 shares issued up... More »
September 20, 2017
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $50 Million of Common Stock
SAN CARLOS, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the pricing of an underwritten public offering of 7,692,308 shares of its common stock at a public offering price of $6.50 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering ... More »
September 19, 2017
Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock
SAN CARLOS, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it intends to offer and sell $50 million of its common stock, subject to market and other conditions, in an underwritten public offering. All of the shares in the offering are to be sold by Iovance. Iovance intends to grant the underwriters a 30-day option... More »
September 13, 2017
Iovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer
SAN CARLOS, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the approval of the Company’s Clinical Trial Application (CTA), by the competent authority (CA) in the Netherlands, for a Phase 2 trial of LN-145 for the treatment of patients with recurrent, metastatic or persistent cervical carcinoma. Iovance initiated the su... More »
September 11, 2017
Iovance Biotherapeutics Partners with TrakCel for Personalized Patient Product Management
SAN CARLOS, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and TrakCel Ltd. today announced a partnership to build a scheduling and logistics tool that automates the supply chain for Iovance's adoptive cell therapy products that utilize its tumor-infiltrating lymphocyte (TIL) technology. The TrakCel Solution will electronically link Iovance with clinical sites, contract manufacturing organizations and couriers to schedule and track TIL therapies for each... More »
September 7, 2017
Iovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State University Comprehensive Cancer Center
Collaboration Focused on Exploring Use of TIL for Lymphoma Indications SAN CARLOS, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it has entered into a preclinical research collaboration with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Ins... More »
September 5, 2017
Iovance Biotherapeutics to Present at Two Upcoming September Conferences
SAN CARLOS, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will webcast a business overview and update by Dr. Maria Fardis, PhD, MBA, Chief Executive Officer of Iovance Biotherapeutics at the following upcoming investor conferences: Rodman & Renshaw 19th Annual Global Investment Conference in New York,... More »
August 31, 2017
Iovance Biotherapeutics Announces FDA Fast Track Designation for LN-144 for Treatment of Advanced Melanoma
SAN CARLOS, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LN-144, the Company’s adoptive cell therapy using its TIL technology, for the treatment of advanced melanoma. “We are pleased that the FDA has granted Fast Track designati... More »
August 31, 2017
Iovance Biotherapeutics to Present Data at Upcoming ESMO 2017 Congress on Tumor-Infiltrating Lymphocyte Treatment for Lymphoma Indications
SAN CARLOS, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced release of an abstract that will be presented in a poster at the upcoming European Society for Medical Oncology (ESMO) 2017 Congress from September 8 -12 in Madrid, Spain. Abstracts are available to the public online on the ESMO website: www.esmo.org. Details of... More »
August 16, 2017
Iovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer
SAN CARLOS, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the first patient was dosed in its C-145-04 Phase 2 trial of LN-145 for the treatment of patients with recurrent, metastatic or persistent cervical carcinoma. “This marks an important milestone for Iovance, as patient dosing is now ongoing in all three of ... More »
August 8, 2017
Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer
SAN CARLOS, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the appointment of Timothy E. Morris as Chief Financial Officer of the company, effective August 14, 2017. Mr. Morris has over 30 years of strategic financial and operating experience in the biotechnology sector. “We are very pleased to welcome Tim as CFO of ... More »
August 1, 2017
Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results
- Company to Host Conference Call at 5:00pm ET Today - SAN CARLOS, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its second quarter 2017 financial results and provided a corporate update. "During the second quarter of 2017, we made significant progress with our robust immuno-oncology pipeline based on our TIL technolo... More »
July 25, 2017
Iovance Biotherapeutics to Host Conference Call to Discuss Second Quarter 2017 Financial and Operating Results on Tuesday, August 1, 2017
SAN CARLOS, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its second quarter 2017 financial and operating results after the close of the U.S. financial markets on Tuesday, August 1, 2017. Management will host a conference call and live audio webcast to discuss these results and provide a business up... More »
June 27, 2017
Lion Biotechnologies, Inc. Changes Name to Iovance Biotherapeutics, Inc.
Name change reflects company’s focus in advancing the field of immuno-oncologyCompany to trade on NASDAQ under ticker IOVA at market open on June 28, 2017SAN CARLOS, Calif., June 27, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it changed its corporate name from Lion Biotechnologies, Inc. to Iovance Biotherapeutics, Inc. The compan... More »
June 5, 2017
Lion Biotechnologies Announces Updated Data at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting from Ongoing LN-144 Phase 2 Clinical Trial
Data show clinically-meaningful outcomes in advanced metastatic melanoma patients who were all refractory to anti-PD-1 and most to anti-CTLA-4 with a median of three prior therapies SAN CARLOS, CA -- (Marketwired) -- 06/05/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced a poster presentation of additional data from 16 patients enrolled in the first cohort o... More »
June 1, 2017
Lion Biotechnologies Announces First Patient Dosed in Phase 2 Trial of LN-145 for Head and Neck Cancer
SAN CARLOS, CA -- (Marketwired) -- 06/01/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the first patient was dosed in its Phase 2 trial of LN-145 for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. "We are pleased to have dosed our first patient in this trial evaluating LN-145 for the treatment ... More »
May 30, 2017
Lion Biotechnologies to Present at Jefferies 2017 Healthcare Conference
SAN CARLOS, CA -- (Marketwired) -- 05/30/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that President and Chief Executive Officer, Dr. Maria Fardis will present an overview of Lion's recent progress and 2017 plans at the upcoming Jefferies 2017 Healthcare Conference on Tuesday, June 6, 2017 at 8:30 a.m. E.T. in New York, NY. A live webcast of the present... More »
May 25, 2017
Lion Biotechnologies Announces Departure of Chief Financial Officer
SAN CARLOS, CA -- (Marketwired) -- 05/25/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Gregory Schiffman, Chief Financial Officer, has decided to leave the company for personal reasons, preventing him from commuting from his residence in Portland, OR to the Company's corporate headquarters in San Carlos, CA. Mr. Schiffman will remain in his current rol... More »
May 19, 2017
Lion Biotechnologies Announces First Patient Dosed in Second Cohort of LN-144 Phase 2 Trial for Metastatic Melanoma
SAN CARLOS, CA -- (Marketwired) -- 05/19/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the first patient was dosed in the second cohort of its ongoing Phase 2 trial of LN-144 for the treatment of patients with metastatic melanoma. This cohort utilizes the company's generation 2 manufacturing process which includes cryopreservation of the outbound produ... More »
May 17, 2017
Lion Biotechnologies to Present New Data from Ongoing LN-144 Phase 2 Clinical Trial at 2017 American Society of Clinical Oncology Annual Meeting
SAN CARLOS, CA -- (Marketwired) -- 05/17/17 -- Poster to highlight new interim data from cohort one of ongoing Phase 2 trial of LN-144 in patients with metastatic melanoma First data readout for Lion-sponsored clinical trial investigating TIL Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology... More »
May 1, 2017
Lion Biotechnologies Reports First Quarter 2017 Financial Results
Company to Host Conference Call at 5:00pm ET Today SAN CARLOS, CA -- (Marketwired) -- 05/01/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its first quarter 2017 financial results and provided a corporate update. "We started 2017 with a clear focus on execution toward expanding our manufacturing capacity, our clinical program and initiatio... More »
April 26, 2017
Lion Biotechnologies Announces New Manufacturing Services Agreement with PharmaCell
COLLABORATION WILL ESTABLISH OVERSEAS CAPACITY FOR MAKING TIL PRODUCTSAN CARLOS, CA -- (Marketwired) -- 04/26/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology (TIL), today announced that it has entered into a new three-year Manufacturing Services Agreement and related statements of work with PharmaCell B.V. (PharmaCell), a contract manufacturing services company based in the Net... More »
April 24, 2017
Lion Biotechnologies to Host Conference Call to Discuss First Quarter 2017 Financial and Operating Results on Monday, May 1, 2017
SAN CARLOS, CA -- (Marketwired) -- 04/24/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2017 financial and operating results after the close of the U.S. financial markets on Monday, May 1, 2017. Management will host a conference call and live audio webcast to discuss these results and provide a business updat... More »
April 19, 2017
Lion Biotechnologies Announces Strategic Alliance with MD Anderson Cancer Center to Conduct Clinical Trials of TILs in Multiple Solid Tumors
SAN CARLOS, CA and HOUSTON, TX -- (Marketwired) -- 04/19/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology and The University of Texas MD Anderson Cancer Center, today announced a multi-year strategic alliance agreement involving multi-arm clinical trials to evaluate the safety and efficacy of TIL therapy in ovarian cancer, various sarcomas, and pancreatic cancer. In ad... More »
April 18, 2017
Lion Biotechnologies Highlights Publication of New Translational Data in Science for TIL Therapy for Treatment of Cervical Cancer
SAN CARLOS, CA -- (Marketwired) -- 04/18/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, highlighted today that a publication in the journal Science provided new translational data from a clinical trial of TIL therapy for the treatment of advanced metastatic cervical cancer conducted at the Surgery Branch of the National Cancer Institute (NCI). This trial has be... More »
March 7, 2017
Lion Biotechnologies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update
Company to Host Conference Call at 4:30pm ET Today SAN CARLOS, CA -- (Marketwired) -- 03/07/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its fourth quarter and full-year 2016 financial results and provided a corporate update. "During the second half of 2016, we significantly expanded our employee base, optimized the process of manufactu... More »
February 28, 2017
Lion Biotechnologies to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial and Operating Results on Tuesday, March 7, 2017
SAN CARLOS, CA -- (Marketwired) -- 02/28/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its fourth quarter and full year 2016 financial and operating results after the close of the U.S. financial markets on Tuesday, March 7, 2017. Management will host a conference call and live audio webcast to discuss these results and provi... More »
February 27, 2017
Lion Biotechnologies to Present at Upcoming Investor Conferences in March
SAN CARLOS, CA -- (Marketwired) -- 02/27/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, announced today that company management will present a corporate update at two investor conferences in March: Cowen and Company 37th Annual Health Care Conference in Boston, MA on Monday, March 6, 2017 at 4:40 p.m. ET 29th Annua... More »